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Abstract:  
Background: 
Improvements in cognitive function are described after initiation of combination antiretroviral 
therapy (cART), with sparse data on differences between cART strategies.  
Methods: 
We assessed changes in cognition, over 96 weeks, in therapy naïve HIV-positive adults randomised 
to darunavir/ritonavir (800/100mg once daily) with either raltegravir (400mg twice daily, Arm1) or 
tenofovir/emtricitabine (245/200mg once daily, Arm2). Seven cognitive tests were administered at 
baseline and week 96. Changes from baseline in individual cognitive test scores and composite score 
(NPZ) were assessed. Comparisons between treatment arms were by intention-to-treat and 
associations with immunological and virological parameters by regression models. 
Findings: 
Of 343 subjects enrolled, 208 completed the week 96 cognitive assessment. Baseline median (IQR) 
CD4+ count and plasma HIV RNA was 348(282-398) cells/uL and 4.7(4.2-5.1) log10 copies/mL, 
respectively. At week 96, numbers with plasma HIV RNA undetectable and remaining on randomised 
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cART were 85(92%) and 110(96%), and 84(90%) and 107(93%) in Arm1 and Arm2, respectively. 
Overall, performance significantly improved by week 96 in 5 of 7 individual tests and in NPZ. Mean 
change in NPZ was 0.28 versus 0.21 for Arm1 and 2, respectively (p=0.37). No statistically significant 
differences between study treatment arms were observed in individual cognitive domains apart 
from attention (greater improvement in Arm1, p=0.0499).  At week 96, NPZ-score increase was 
associated with increase in CD4+ (p=0.001) but not HIV RNA area-under-curve (p=0.60).  
Interpretation: 
Subsequent to the initiation of cART, immunological recovery rather than type of antiretroviral 
therapy is the major driver of changes in cognitive function. 
 
Keywords: 
HIV; antiretroviral therapy; cognitive function; nucleoside sparing; randomised clinical trial. 
 
Manuscript: 
Introduction: 
Modern combination antiretroviral therapy (cART) has many beneficial effects on the central 
nervous system (CNS). Rates of HIV-dementia and other CNS opportunistic diseases have declined 
dramatically since the advent and widespread availability of cART 
1,2
 and in general, cognitive 
function improves after commencing antiretroviral therapy 
3-5
. Despite these advances, impairment 
in cognitive function remains prevalent in otherwise effectively cART treated HIV-positive subjects 
6
. 
The presence of such cognitive impairment is reported to impact on individuals’ ability to maintain 
employment, undertake activities of daily living and comply with antiretroviral medication and has 
been associated with poorer overall survival 
7
. 
 
Data on changes in overall cognitive function and changes in individual cognitive domains in HIV-
positive subjects commencing different cART regimens are sparse and no data exist on changes in 
cognitive function in therapy naïve individuals commencing novel antiretroviral strategies. The aim 
of this study was to prospectively evaluate changes in cognitive function in HIV-positive 
antiretroviral naïve subjects randomised to commence either a standard cART regimen of  
darunavir/ritonavir plus tenofovir/emtricitabine or a novel nucleos(t)ide-reverse-transcriptase-
inhibitor (NRTI)-sparing cART regimen of darunavir/ritonavir plus raltegravir. 
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As systemic HIV replication is a risk factor for cognitive impairment 
8
 (and HIV RNA in blood is 
independently associated with cognitive impairment), given a more rapid HIV RNA suppression is 
reported with the use of integrase-inhibitor containing antiretroviral regimens 
9
 we hypothesized 
that the participants in the NRTI-sparing, raltegravir-containing treatment arm would have a more 
favourable evolution in cognitive function compared to the darunavir/ritonavir + 
tenofovir/emtricitabine arm. 
 
 
Methods: 
Subject selection 
Antiretroviral therapy naïve adults entering the NEAT001/ANRS143 study 
10
 at selected sites were 
eligible to enter this cognitive sub-study. Participating sites were located in Belgium, France, 
Germany, Ireland, Italy, Spain and the United Kingdom, as validated cognitive tests were available in 
the languages of these countries. Further detailed eligibility criteria have been described previously 
11
. In brief, eligible subjects were required to have a CD4+ lymphocyte count below 500 cells/uL or 
symptomatic HIV-infection. Specific sub-study exclusion criteria were current or past opportunistic 
infections or tumors of the central-nervous-system, non HIV-related major neurological or 
psychiatric disorders, active recreational drug use and linguistic difficulties. Human ethics committee 
approval was gained at all participating sites, and all subjects provided written informed consent for 
the core trial and sub-study participation. 
 
Participants were randomly assigned in a 1:1 ratio to receive oral open-label therapy comprising 800 
mg darunavir and 100 mg ritonavir once daily with either 400 mg twice daily raltegravir (Arm1, NRTI-
sparing) or 245/200 mg once daily tenofovir/emtricitabine (Arm 2, standard therapy).  
Randomisation was stratified by country, and sub-study consent was obtained prior to 
randomisation to limit imbalanced distribution of baseline characteristics between the sub-study 
arms. 
 
Study procedures 
A standardised cognitive assessment battery was undertaken at baseline and after 96 weeks of 
antiretroviral therapy by trained study staff. The battery was specifically chosen to assess the 
cognitive domains reported to be affected in chronic HIV-infection 
12
, and deemed practical to 
undertake in a large multicentre study. In addition, Lawton’s questionnaire of Instrumental Activities 
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of Daily Living (5 items) and a short questionnaire to assess the patient’s perception of cognitive 
abilities (6 items 
13
) were undertaken to assess patient reported outcomes. 
 
The cognitive battery comprised of trail making test (TMT) part A and B (attention and mental 
flexibility) 
14
, digit symbol substitution test (psycho-motor speed) 
15
, backward digit span task 
(working memory) 
15
, free and cued selective reminding test (retrieval ability and episodic memory) 
16
, semantic and formal fluency tests (verbal fluency) and the frontal assessment battery (frontal 
executive function) 
17
.  
 
Statistical analysis 
The primary outcomes were psychomotor speed and overall cognitive function at week 96. 
Secondary outcomes were all other individual cognitive testing results and patient reported 
outcomes. Sample size was estimated from data gathered from the ANRS CO3 Aquitaine Cohort 
18
. 
Assuming that mean score on the digit symbol substitution test is 44.5 (SD 12.9) and that a 
difference of 10% would be of clinical significance, a sample size of 182 subjects in each study 
treatment arm would be required to detect this difference between the two study treatment groups 
with 90% power and with a significance level of 5%. Due to possible study dropouts, a sample size of 
400 subjects (200 per study arm) was proposed. 
 
A composite cognitive score (NPZ) was calculated from the 7 neuropsychological tests. For this, raw 
test scores were first transformed to z-scores at W0 and W96, respectively, by subtracting the mean 
and dividing by the standard deviation of the total study sample at baseline. TMT-A and B were log10-
transformed, and the signs reversed so that for all tests a score above zero would denote above-
average and scores below zero denote below-average cognitive function within the study 
population. The NPZ was then calculated as the average of the 7 individual z-scores at W0 and W96, 
respectively, in participants with ≤1 missing test. Activities of daily living and cognitive complaints 
were analysed as binary outcome (any help needed / any complaint), and cumulative score.  
 
For each test and NPZ, week 96 results were compared between the arms using multivariable linear 
regression of absolute values, adjusting for the baseline value. Similarly, activities of daily living and 
cognitive complaints at week 96 were analysed using ordered and logistic regression. The primary 
analysis excluded participants with missing week 96 data, and was adjusted for years of education, 
ethnic group and age at baseline (because of strong correlation with test results), and multiple 
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imputation was used to impute missing baseline values from the same three factors using Stata’s mi 
impute command (version 13.1) creating 25 simulations. 
 
Various sensitivity analyses were performed including analysis of only patients with non-missing 
baseline results (complete cases), adjusting for baseline test results only, multiple imputation 
additionally using other cognitive test results or other covariates, or using mixed effect regression 
models.  
 
We examined the association of early HIV RNA suppression (<50 copies/mL at a) week 8 or b) week 
12) with week 96 NPZ-score using multivariable regression models, adjusting for randomised arm, 
age, ethnicity, education, baseline HIV RNA and baseline NPZ. We also looked at HIV RNA area under 
the curve until week 96. In similar but post-hoc analyses,  we assessed the association between 
CD4+ and CD8+ lymphocyte count with week 96 NPZ-score, examining area under the curve, week 
96 result and (for CD4+) time to reach a count above 500 cells/uL as possible explanatory variables.  
 
All significance tests were two-sided, and raw p values without multiplicity adjustment are shown.  P 
values < 0.05 were considered statistically significant. 
 
 
Results: 
Participant characteristics 
Of 343 participants enrolled, 302 had at least one cognitive assessment: 283 (94%) at baseline, and 
208 (69%) at week 96, with 189 subjects completing both assessments. A consort diagram describing 
participant numbers is shown in Figure 1. Baseline characteristics of participants with week 96 
results are shown in Table 1. 
 
Of these 208 subjects, 91% were male, 10% of black ethnicity and mode of HIV-acquisition was men-
having-sex-with-men (MSM) in 70%. On comparing the baseline characteristics of the 208 subjects 
who completed the week 96 cognitive assessment battery with the rest of the NEAT001/ANRS143 
study population there were no statistically significant differences in randomisation arm, age, 
ethnicity, weight, smoking status or HIV viral load. Differences were present in years of known HIV-
infection and nadir CD4+ cell count (1.1 years (IQR 0.2 to 3.1) versus 1.3 year (IQR 0.3 to 3.8) and 304 
cells/uL (IQR 235 to 370) versus 329 cells/uL (IQR 261 to 378) for the main study only versus the sub-
study population, respectively). Differences were also present in country subjects were recruited 
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from (11% versus 7%, 24% versus  41%, 12% versus 15%, 9% versus 29% and 45% versus 7% of 
subjects recruited from  Spain, France, the United Kingdom, Italy and other countries for the main 
study versus this sub-study, respectively). 
 
At the time of week 96 cognitive testing, 84/93 (90%) and 107/115 (93%) subjects in Arm1 and Arm2 
remained on randomised therapy. There were no significant differences in the proportion of patients 
with plasma HIV RNA <50 copies/mL (7 (92%) and 5 (96%), respectively, p=0.32), in CD4+ cell count 
(mean 604 and 584 cells/uL, respectively, p=0.49) or in CD4+ cell count change from baseline (mean 
267 and 257 cells/uL in Arm1 and Arm2, respectively, adjusted for baseline CD4+; p=0.67). 
 
Changes in cognitive function over 96 weeks 
Results on changes in individual cognitive domains and overall cognitive function from multivariable 
linear regression models and adjusted for age, education and ethnicity are shown in Table 2. Overall, 
performance significantly improved by week 96 in all individual cognitive tests, except for TMT-B and 
Verbal Fluency Test. There was no statistically significant difference between the arms in change of 
any of the tests apart from TMT-A (p=0.0499), which showed a greater improvement in Arm1 versus 
Arm2. Mean increase in NPZ was 0.28 and 0.21 in Arm1 and Arm2, respectively (difference -0.07 
(95% CI -0.23 to 0.09); p=0.37). 
Results of sensitivity analyses were similar (data not shown). For TMT-A, the p-value became 
smaller, for example in the complete case (p=0.016); of note, the difference of 0.04 on the log10 scale 
corresponds to a 10% (~4 sec) faster time to complete the task in Arm1. 
 
Patient reported outcomes 
At week 96, 1/93 (1%) participants in Arm1 and 6/114 (5%) in Arm2 reported to need help in at least 
one activity of daily living (adjusted p= 0.080), and 30/93 (32%) and 47/114 (41%), respectively, 
reported one or more cognitive complaints (adjusted p= 0.16). There also was no difference 
between study treatment arms when analysing cumulative scores of patient reported outcomes.  
 
Associations between cognitive function and changes in virological and immunological parameters 
At weeks 8 and 12, 60/90 (67%) and 70/92 (76%) participants in Arm1 and 36/114 (32%) and 59/113 
(52%) in Arm2 had HIV RNA < 50 copies/mL. From week 24 onwards there were no differences 
between the study arms (>85% in both). For neither HIV RNA < 50 copies/mL at week 8 (-0.05 versus 
≥ 50 copies/mL (95% CI -0.18 - 0.08); p=0.44) nor at week 12 (-0.10 (95% CI -0.22 - 0.02); p=0.09) was 
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there evidence of an association with NPZ-score at week 96, and similarly for HIV RNA area under 
the curve (p=0.60). 
In contrast, we found that a greater increase in CD4+ cell count to week 96 was statistically 
significantly associated with greater improvement in NPZ-score (0.05 (95% CI 0.02-0.08) higher NPZ-
score per 100 cells/µL more increase; p=0.001) in multivariable models. A similar association with 
NPZ-score change was found for the average CD4+ count from week 0 to week 96 as measured by 
area under the curve (p=0.006) whereas time to reach a CD4+ count >= 500 cells/uL was not 
associated with NPZ-score at week 96 (p=0.79). No statistically significant associations were 
observed between change in CD8+ count and NPZ change (0.00 per 100 cells/µL more (95% CI -0.02 - 
0.02), p=0.78); when jointly looking at CD4+ and CD8+, the significant association of CD4+ with NPZ-
score remained statistically significant and unchanged compared with model without CD8+ whereas 
CD8+ was not associated.  
 
 
Discussion: 
To our knowledge, this is the first longitudinal randomised comparison of the effects of NRTI-sparing 
cART to standard therapy on cognitive function in HIV-positive individuals initiating therapy. We 
found no evidence of differences in changes in overall cognitive function or specific cognitive 
domains between the treatment arms we assessed, but observed change in CD4+ lymphocyte count 
to be the factor most strongly associated with the evolution of changes in cognitive function. 
 
Previous studies have reported cognitive benefits after commencing cART 
5
, although no benefit in 
changes in cognitive function has been reported in patients commencing cART at high CD4+ counts 
above 500 cells/uL 
19
. Improvements in cognition in longitudinal studies may in part be secondary to 
practice effects 
20
. By undertaking only two cognitive assessments 96 weeks apart we may have 
minimised the impact of such a practise effect due to this relatively long time interval between 
cognitive testing. Few studies have included randomised comparisons of different cART regimens. In 
two prospective studies comparing cognitive function in HIV-positive subjects initiating different 
cART regimens, poorer cognitive outcomes have been reported in subjects allocated to receive 
efavirenz-containing cART regimens compared to outcomes in subjects allocated to receive other 
standard cART regimens 
21,22
. However no studies have assessed NRTI-sparing cART regimens. 
 
Cognitive function has been examined within longitudinal studies assessing other novel antiretroviral 
strategies. In treatment-experienced patients on suppressive antiretroviral therapy switching to 
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protease-inhibitor monotherapy, no significant difference in cognitive function was reported 
compared to patients remaining on standard cART 
23,24
. Our study differs from this approach in 
several ways. First, we have assessed cognitive function in therapy naïve subjects electively 
commencing antiretroviral therapy, rather than subjects switching from an already virological 
suppressive antiretroviral regimen. Second, the strategy we have assessed was an NRTI-sparing 
antiretroviral strategy, comprised of two active antiretroviral agents, namely darunavir and 
raltegravir, not one active antiretroviral agent as is the case with protease-inhibitor monotherapy.  
 
We hypothesized that the participants in the NRTI-sparing, raltegravir-containing treatment arm 
would have a more favourable evolution in cognitive function compared to the darunavir/ritonavir + 
tenofovir/emtricitabine arm. The rationale for this being patients on the integrase-inhibitor 
containing arm may achieve undetectable plasma HIV RNA more rapidly compared to the non-
integrase-inhibitor containing cART strategy. Our study is one of the first to assess  associations 
between the rate of decay of HIV RNA with evolution of cognitive function. As expected, in our study 
time to undetectable HIV RNA was slightly faster in Arm1 with the number of subjects with HIV RNA 
<50 copies/mL greater at weeks 8 and 12 than in Arm2. We did not observe any associations 
between measures of HIV RNA in our study and cognitive function at week 96. However, if changes 
in cognition associated with the speed of plasma HIV RNA decay were to have occurred and only be 
evident during the early phase after commencing antiretroviral therapy which disappears at a later 
stage, we would not have observed such changes given the timing of the cognitive assessments in 
our study. 
The magnitude of CD4+ count recovery after the initiation of antiretroviral therapy has been 
reported to be associated with the degree of improvement in cognitive function previously 
25
. 
Interestingly we observed significant associations between change in CD4+ count to week 96 with 
overall changes in cognitive function in multivariable models. These associations were not present 
with CD8+ count. These data suggest that immune system recovery is associated with improvements 
in cognitive function in therapy naïve HIV-positive individuals after the initiation of antiretroviral 
therapy. The lack of significant difference in changes in cognitive function between the two 
treatment arms assessed in our study may be related to the lack of a significant difference in 
changes in CD4+ counts between the treatment arms. 
 
Based on our initial sample size calculation, we aimed for a total study population of 400 subjects 
with approximately 200 subjects in each treatment arm. Although we recruited 343 subjects to this 
study, only 208 subjects completed the week 96 cognitive testing and were included in our analysis. 
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Based on the assumptions we made to calculate the sample size, our study was underpowered. 
However our sample size, of approximately 100 subjects in each treatment arm, compared to other 
studies represents a relatively large number of subjects to undertake basic cognitive observations. 
This sub-study involved cognitive testing at baseline and then after 96 weeks, with no interval 
testing. This relatively long interval and the duration of the cognitive battery we utilised may be 
factors which have influenced the poor retention to the sub-study procedures. Interval cognitive 
testing at more frequent intervals, such as yearly intervals, would have provided further information 
on the dynamics of cognitive changes within this study and therefore strengthened the statistical 
analysis. This also may have enhanced the retention of subjects to the sub-study if it was not the 
duration of the cognitive battery which limited retention. However the available resources did not 
permit us to increases the number of cognitive testing visits within this sub-study. A further 
limitation was the lack of measurement of CSF HIV RNA, which may have provided more strength in 
the findings we have reported. 
 
We observed trends for numerically greater improvements in 5 out of the 7 cognitive domains 
assessed and in global cognitive score in Arm1 (NRTI-sparing) compared to Arm2. However, apart 
from TMT-A these changes were not statistically significant and the magnitude of the differences 
between the arms were generally small; for instance difference in NPZ score between the treatment 
arms was 0.07 with a change in z-score approximately 0.5 often considered of clinical relevance. 
Given the observations we have made are all of a small magnitude we do not consider them to be of 
clinical relevance and acknowledge that the differences in TMT-A could be a chance finding. 
 
In summary, our observations suggest subsequent to the initiation of antiretroviral therapy, 
immunological recovery rather than type of antiretroviral therapy is the major factor associated with 
changes in cognitive function. 
 
Presentation of results: 
Some of the data contained in this manuscript was presented as an oral presentation at the 15th 
European AIDS Conference (Barcelona, Spain, October 21-24, 2015; abstract number PS11/6). 
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Table 1: 
Baseline characteristics for all subjects with W96 cognitive data. 
 DRV/r+RGV DRV/r+TDF/FT
C 
Overall  
Factor N=93 N=115 N=208 p-value 
Gender:  male 
   female 
87 (94%) 
6 (6%) 
102 (89%) 
13 (11%) 
189 (91%) 
19 (9%) 
0.23 
Age (years) 36 (31-46) 41 (31-48) 40 (31-47) 0.053 
Origin:   black 
  caucasian 
  other 
11 (12%) 
77 (83%) 
5 (5%) 
10 (9%) 
101 (88%) 
4 (3%) 
21 (10%) 
178 (86%) 
9 (4%) 
0.58 
Mode of HIV infection: 
 homosexual/bisexual 
 heterosexual 
 other/unknown 
 
72 (77%) 
18 (19%) 
3 (3%) 
 
74 (64%) 
32 (28%) 
9 (8%) 
 
146 (70%) 
50 (24%) 
12 (6%) 
0.10 
HIV stage:  Stage A 
  Stage B 
  Stage C 
83 (89%) 
9 (10%) 
1 (1%) 
101 (88%) 
10 (9%) 
4 (3%) 
184 (88%) 
19 (9%) 
5 (2%) 
0.52 
Education (years) 13 (10-17) 13 (10-15) 13 (10-16) 0.19 
Years since first positive HIV 
serology 
1 (0-3) 2 (0-4) 1 (0-4) 
0.21 
CD4 nadir (cells/uL) 332 (254-370) 327 (268-383) 330 (262-379) 0.53 
CD4 (cells/uL) 348 (280-393) 347 (286-401) 348 (282-398) 0.80 
HIV-RNA (log10 copies/mL) 4.8 (4.3-5.2) 4.7 (4.2-5.0) 4.7 (4.2-5.1) 0.13 
Height (cm) 176 (172-181) 175 (170-180) 175 (171-180) 0.27 
Weight (kg) 74 (65-81) 71 (63-80) 73 (64-81) 0.44 
Systolic blood pressure (mmHg) 120 (114-130) 120 (110-130) 120 (110-130) 0.45 
CNS-related disorder at screening 3 (3%) 8 (7%) 11 (5%) 0.23 
Country:  France 
  Spain 
  UK 
  Italy 
  Other country 
38 (41%) 
7 (8%) 
13 (14%) 
30 (32%) 
5 (5%) 
48 (42%) 
8 (7%) 
18 (16%) 
31 (27%) 
10 (9%) 
86 (41%) 
15 (7%) 
31 (15%) 
61 (29%) 
15 (7%) 
0.84 
Smoking:  Never smoked 
  Stopped 
  Current 
56 (60%) 
5 (5%) 
32 (34%) 
50 (43%) 
15 (13%) 
50 (43%) 
106 (51%) 
20 (10%) 
82 (39%) 
0.030 
Hepatitis C, any marker positive 2 (2%) 5 (4%) 7 (3%) 0.38 
Free Selective Reminding Test * 
(Cumulative number of words 
recalled) 
35 (30-38) 34 (30-37) 34 (30-38) 0.14 
Digit Symbol Substitution Task * 
(Number of correct marks) 
53 (41-59) 55 (41-64) 55 (41-61) 0.43 
Trial Making Test A † 30 (25-41) 33 (27-41) 32 (26-41) 0.26 
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(Time to completion [(secs]) 
Trial Making Test B † 
(Time to completion [secs]) 
57 (45-83) 62 (49-83) 58 (47-83) 0.41 
Verbal Fluency Test * 
(Number of words named) 
34 (29-40) 33 (29-41) 33 (29-40) 0.80 
Backwards Digit Span * 
(Number of digits) 
4 (3-5) 4 (3-5) 4 (3-5) 0.85 
Frontal Assessment Battery 
(cumulative score) * 
18 (17-18) 18 (16-18) 18 (16-18) 0.55 
 
Table 1 Legend:  
number (percentage) or median (interquartile range) are presented. * higher score represents better 
performance; † lower score represents beHer performance. 
 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
NEAT 001 cognitive sub study 
Page 3 of 3 
Table 2: 
Changes in cognitive function scores over 96 weeks between study treatment arms.  
 
Cognitive domain 
N available, mean change (±SE) to week 96 Difference between 
arms 
 
Overall  
(p-value for 
change) 
(n=208) 
Arm1 
DRV/r/RTG 
(n=93) 
Arm2 
DRV/r/TDF/FT
C 
(n=115) 
(95% CI) 
 
 
p-
value 
for 
differe
nce 
 
Free Selective Reminding 
Test * 
(Cumulative number of 
words recalled) 
 
n=200 
2.45 ± 0.34 
(p<0.001) 
n=91 
2.57 ± 0.48 
 
n=109 
2.34 ± 0.44 
 
-0.24 
(-1.47 - 1.00) 
 
0.706 
 
 
Digit Symbol Substitution 
Task * 
(Number of correct 
marks) 
 
n=195 
2.64 ± 1.08 
(p=0.016) 
n=86 
4.17 ± 1.64 
 
n=109 
1.42 ± 1.41 
 
-2.74 
(-6.98 - 1.49) 
 
0.203 
 
 
Trial Making Test A † 
(Time to completion [log10 
secs]) 
 
n=204 
-0.03 ± 0.01 
(p=0.004) 
n=91 
-0.05 ± 0.01 
 
n=113 
-0.01 ± 0.01 
 
0.04 
(0.00 - 0.07) 
 
0.0499 
 
 
Trial Making Test B † 
(Time to completion [log10 
secs]) 
 
n=203 
-0.02 ± 0.01 
(p=0.179) 
n=90 
-0.02 ± 0.02 
 
n=113 
-0.01 ± 0.02 
 
0.01 
(-0.03 - 0.05) 
 
0.637 
 
 
Verbal Fluency Test * 
(Number of words 
named) 
 
n=201 
0.49 ± 0.58 
(p=0.402) 
n=91 
0.37 ± 0.87 
 
n=110 
0.59 ± 0.78 
 
0.22 
(-2.06 - 2.51) 
 
0.848 
 
 
Backwards Digit Span * 
(Number of digits) 
 
n=206 
0.24 ± 0.08 
(p=0.005) 
n=91 
0.21 ± 0.12 
 
n=115 
0.27 ± 0.11 
 
0.07 
(-0.26 - 0.39) 
 
0.690 
 
 
Frontal Assessment 
Battery 
(cumulative score) * 
 
n=198 
0.30 ± 0.10 
(p=0.004) 
n=88 
0.37 ± 0.14 
 
n=110 
0.24 ± 0.13 
 
-0.14 
(-0.50 - 0.23) 
 
0.458 
 
 
NPZ score * 
 
 
n=197 
0.24 ± 0.04 
(p<0.001) 
n=87 
0.28 ± 0.06 
 
n=110 
0.21 ± 0.05 
 
-0.07 
(-0.23 - 0.09) 
 
0.373 
 
 
 Table 2 legend: * higher score represents an improvement; † lower score represents an 
improvement. All results shown are from multivariable linear regression models and adjusted for 
age, education, ethnicity and baseline test (missing data imputed). 
 
 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
NEAT 001 cognitive sub study 
Page 1 of 1 
Figure 1: 
Study Consort 
Diagram
 
 
 
 
Participants enrolled into cognitive substudy: n=343 
164 DRV/r/RTG 
 
   135 with baseline neurocognitive examination 
179 DRV/r/TDF/FTC 
 
   148 with baseline neurocognitive examination 
15 did not have week 96 trial visit 
     12 withdrawal or lost to follow-up 
       3 did not attend clinic 
6 did not have week 96 trial visit 
     4 withdrawal or lost to follow-up 
     2 did not attend clinic 
 
93 with week 96 neurocognitive examination 
     85 also with baseline examination 
115 with week 96 neurocognitive examination 
        104 also with baseline examination 
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